-Omics and cancer biomarkers: link to the biological truth or bear the consequences.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. The impact of ultraviolet- and infrared-based laser microdissection technology on phosphoprotein detection in the laser microdissection-reverse phase protein array workflow.Clinical proteomics · 2020
   Article
2. An individualized gene expression signature for prediction of lung adenocarcinoma metastases.Molecular oncology · 2017
   Article
3. Proteomic Profiling of Serial Prediagnostic Serum Samples for Early Detection of Colon Cancer in the U.S. Military.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017
   Article
4. Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics.Scientific reports · 2017
   Article
5. Translational cancer research: balancing prevention and treatment to combat cancer globally.Journal of the National Cancer Institute · 2015
   Article
6. Reverse phase protein arrays: mapping the path towards personalized medicine.Molecular diagnosis & therapy · 2014
   Review
7. Proteogenomic convergence for understanding cancer pathways and networks.Clinical proteomics · 2014
   Review
8. PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine.Asian journal of andrology · 2013
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as